Modus Therapeutics completes directed issue raising MSEK 7.6
KDventures AB says its portfolio company Modus Therapeutics carried out a directed issue of MSEK 7.6. Net proceeds will finance the 2027 development plan for sevuparin.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.